Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Account Payables (2016 - 2025)

Viking Therapeutics' Change in Account Payables history spans 12 years, with the latest figure at $48.8 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 410.8% year-over-year to $48.8 million; the TTM value through Dec 2025 reached $43.4 million, up 1786.15%, while the annual FY2025 figure was $43.4 million, 1786.15% up from the prior year.
  • Change in Account Payables for Q4 2025 was $48.8 million at Viking Therapeutics, up from -$1.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $48.8 million in Q4 2025 and bottomed at -$10.8 million in Q3 2024.
  • The 5-year median for Change in Account Payables is -$268500.0 (2021), against an average of $2.5 million.
  • The largest annual shift saw Change in Account Payables skyrocketed 563.74% in 2022 before it plummeted 10935.0% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$1.4 million in 2021, then surged by 487.55% to $5.4 million in 2022, then crashed by 66.57% to $1.8 million in 2023, then soared by 430.87% to $9.6 million in 2024, then skyrocketed by 410.8% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Change in Account Payables are $48.8 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.2 million (Q2 2025).